Positive results from CheckMate-205 study for Opdivo (nivolumab) in treatment of classical Hodgkin lymphoma- BMS

Bristol-Myers Squibb announced results from CheckMate -205, a multi-cohort, non-comparative, single-arm, Phase II registrational trial evaluating Opdivo (nivolumab) in patients with classical Hodgkin lymphoma (cHL). These results, from cohort B of the trial, included patients who had relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin (n=80).

The primary endpoint of objective response rate (ORR) per an independent radiologic review committee (IRRC) was 66.3% (95% CI: 54.8-76.4). Median time to response was 2.1 months, and estimated median duration of remission was 7.8 months (95% CI: 6.6-NE). The majority of responses (62.3%) were ongoing at the time of analysis. In an exploratory analysis, the authors observed more than two-thirds (72.1%) of patients who did not respond to most recent prior brentuximab vedotin treatment did respond to Opdivo. The safety profile of Opdivo in CheckMate -205 was consistent with previously reported data in this tumor type.